BioTheranostics Nicolas Barthelemy its new president and CEO. He succeeds Richard Ding, who will remain chairman of the board of bioTheranostics in addition to heading the Asia Pacific operations for parent company bioMérieux. Barthelemy previously served as chief commercial officer and president of the Cell Systems Division.
AltheaDx announced the appointment of Bruce Bodaken, Karin Eastham, and Jorge Garces its board of directors.
Bodaken served as chairman and CEO of Blue Shield of California from January 2000 to December 2012, and currently serves on the boards of directors of Rite Aid and WageWorks. He also is on the board of directors of the Institute of Medicine's Roundtable on Value and Science-Driven Healthcare, and is a visiting scholar at the Brookings Institution.
Eastham serves on the boards of directors of lllumina, Veracyte, MorphoSys, and Geron. She previously was executive VP, COO, and a member of the board of trustees of the Burnham Institute for Medical Research.
Garces has been president of AltheaDx since February 2014 and the firm's COO since June 2013. Prior to joining AltheaDx, he was senior VP of R&D at GenMark Diagnostics, CEO and president of Enigma Diagnostics, and VP and site operations manager of Hologic.